DrugPatentWatch Database Preview
Details for Patent: 10,478,502
» See Plans and Pricing
Which drugs does patent 10,478,502 protect, and when does it expire?
Patent 10,478,502 protects BRYHALI and DUOBRII and is included in two NDAs.
This patent has seventeen patent family members in eleven countries.
Drugs Protected by US Patent 10,478,502
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | BRYHALI | halobetasol propionate | LOTION;TOPICAL | 209355-001 | Nov 6, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS | Start Trial | |||
| Bausch | DUOBRII | halobetasol propionate; tazarotene | LOTION;TOPICAL | 209354-001 | Apr 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,478,502
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011345240 | Start Trial | |||
| Brazil | 112013012476 | Start Trial | |||
| Canada | 2817524 | Start Trial | |||
| Canada | 3055328 | Start Trial | |||
| China | 103228281 | Start Trial | |||
| European Patent Office | 2643002 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
